289 related articles for article (PubMed ID: 29024804)
1. Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide.
Raiola AM; Risitano A; Sacchi N; Giannoni L; Signori A; Aquino S; Bregante S; Di Grazia C; Dominietto A; Geroldi S; Ghiso A; Gualandi F; Lamparelli T; Tedone E; Van Lint MT; Varaldo R; Ibatici A; Marani C; Marotta S; Guolo F; Avenoso D; Garbarino L; Pane F; Bacigalupo A; Angelucci E
Biol Blood Marrow Transplant; 2018 Jan; 24(1):119-126. PubMed ID: 29024804
[TBL] [Abstract][Full Text] [Related]
2. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.
Kasamon YL; Luznik L; Leffell MS; Kowalski J; Tsai HL; Bolaños-Meade J; Morris LE; Crilley PA; O'Donnell PV; Rossiter N; Huff CA; Brodsky RA; Matsui WH; Swinnen LJ; Borrello I; Powell JD; Ambinder RF; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):482-9. PubMed ID: 19925877
[TBL] [Abstract][Full Text] [Related]
3. Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.
McCurdy SR; Kanakry CG; Tsai HL; Kasamon YL; Showel MM; Bolaños-Meade J; Huff CA; Borrello I; Matsui WH; Brodsky RA; Ambinder RF; Bettinotti MP; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Biol Blood Marrow Transplant; 2018 Feb; 24(2):343-352. PubMed ID: 29055682
[TBL] [Abstract][Full Text] [Related]
4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
6. Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study.
Zou J; Wang T; He M; Bolon YT; Gadalla SM; Marsh SGE; Kuxhausen M; Gale RP; Sharma A; Assal A; Prestidge T; Aljurf M; Cerny J; Paczesny S; Spellman SR; Lee SJ; Ciurea SO
Transplant Cell Ther; 2022 Feb; 28(2):107.e1-107.e8. PubMed ID: 34774819
[TBL] [Abstract][Full Text] [Related]
7. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
8. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
9. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
10. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
11. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
[TBL] [Abstract][Full Text] [Related]
12. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
13. [HLA-haploidentical transplantation with post-transplant cyclophosphamide].
Sugita J
Rinsho Ketsueki; 2017; 58(10):2124-2134. PubMed ID: 28978857
[TBL] [Abstract][Full Text] [Related]
14. Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation.
Kanda J; Ichinohe T; Fuji S; Maeda Y; Ohashi K; Fukuda T; Miyamura K; Iwato K; Eto T; Nakamae H; Kobayashi N; Mori T; Mori S; Morishima Y; Atsuta Y; Kanda Y;
Biol Blood Marrow Transplant; 2015 Feb; 21(2):305-11. PubMed ID: 25464119
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
16. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.
Solomon SR; Aubrey MT; Zhang X; Jackson KC; Morris LE; Holland HK; Solh MM; Bashey A
Blood Adv; 2020 Oct; 4(20):5311-5321. PubMed ID: 33108457
[TBL] [Abstract][Full Text] [Related]
17. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
[TBL] [Abstract][Full Text] [Related]
18. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide.
Mariotti J; Taurino D; Marino F; Bramanti S; Sarina B; Morabito L; De Philippis C; Di Vito C; Mavilio D; Carlo-Stella C; Della Porta M; Santoro A; Castagna L
Cancer Med; 2020 Jan; 9(1):52-61. PubMed ID: 31702882
[TBL] [Abstract][Full Text] [Related]
19. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.
van Rood JJ; Loberiza FR; Zhang MJ; Oudshoorn M; Claas F; Cairo MS; Champlin RE; Gale RP; Ringdén O; Hows JM; Horowitz MH
Blood; 2002 Mar; 99(5):1572-7. PubMed ID: 11861270
[TBL] [Abstract][Full Text] [Related]
20. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
